Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Considering Tricor/Statin Combination On Heels Of Labeling Change

Executive Summary

Abbott is considering developing a Tricor/statin combination product, Pharmaceutical Product Group President Jeffrey Leiden said Jan. 18

You may also be interested in...



Abbott Growth Is Dependent On Full Pipeline, Not Xinlay, CFO Says

Abbott's sales growth predictions for 2006 do not hinge on FDA approval of Xinlay (atrasentan), the company's investigational prostate cancer therapy, Exec VP-Finance and CFO Thomas Freyman said

Abbott Growth Is Dependent On Full Pipeline, Not Xinlay, CFO Says

Abbott's sales growth predictions for 2006 do not hinge on FDA approval of Xinlay (atrasentan), the company's investigational prostate cancer therapy, Exec VP-Finance and CFO Thomas Freyman said

Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma

Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel